4320-94-9

Usage

Uses

Used in Medical and Surgical Procedures:
2-(1H-1,2,3-TRIAZOL-1-YL)ETHANAMINE is used as a hypnotic agent and anesthetic for inducing sedation and anesthesia during medical and surgical procedures. It is favored for its rapid onset of action and short duration, which allows for quick sedation and recovery.
Used in Hospital Settings:
In hospitals, 2-(1H-1,2,3-TRIAZOL-1-YL)ETHANAMINE is used as a sedative and anesthetic agent to facilitate various medical interventions, including surgeries and diagnostic procedures, by providing patients with a state of controlled sedation and pain relief.
Used in Ambulatory Surgery Centers:
At ambulatory surgery centers, 2-(1H-1,2,3-TRIAZOL-1-YL)ETHANAMINE is utilized as an anesthetic to ensure patient comfort during outpatient procedures, with its short duration aiding in quicker recovery times and discharge.
Used in Emergency Departments:
In emergency departments, 2-(1H-1,2,3-TRIAZOL-1-YL)ETHANAMINE is employed as a rapid-acting sedative and anesthetic to manage acute pain and facilitate emergency interventions, providing immediate relief and allowing for necessary treatments to be administered effectively.

InChI:InChI=1/C4H8N4/c5-1-3-8-4-2-6-7-8/h2,4H,1,3,5H2

Upstream product

• 4396-77-4 2-[2-([1,2,3]triazol-1-yl)ethyl]isoindole-1,3-dione 
• 4368-69-8 2-(1H-1,2,3-triazol-1-yl)acetonitrile 

Downstream Products

• 864157-08-4 4-Hydroxy-N-(2-[1,2,3]triazol-1-yl-ethyl)-benzenesulfonamide 
• 1086597-35-4 2-(2-(2-(2-(2-(1H-1,2,3-triazol-1-yl)ethylamino)-5-fluoropyrimidin-4-yl)benzo[b]thiophen-7-yl)phenoxy)ethanol 

Relevant academic research and scientific papers

CINNAMIC ACID AMIDE DERIVATIVE

The present invention provides a cinnamic acid amide derivative having an excellent analgesic action. The cinnamic acid amide derivative of the present invention is a compound showing excellent analgesic actions to not only a nociceptive pain model animal but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains.

TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Novel pentafluorosulfanyl compounds

The present invention provides the compounds of formula I-A their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing th

Novel oxidized thioether derivatives

The present invention provides the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them

ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND

The invention relates to the substituted imidazoles of formula (I) and to methods for producing the same, to their use in the treatment and/or prophylaxis of diseases and to their use for producing drugs for use in the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, especially against cytomegaloviruses.

Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase

To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.